• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [24069 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Nonacog beta pegol (haemophilia B) - Benefit assessment according to §35a Social Code Book V]
2018     Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Prostate artery embolisation: poor design and reporting impact the value of current systematic reviews
2018     NIHR Health Technology Assessment programme Strategy of endovascular versus open repair for patients with clinical diagnosis of ruptured abdominal aortic aneurysm: the IMPROVE RCT
2018     NIHR Health Services and Delivery Research programme NHS managers' use of nursing workforce planning and deployment technologies: a realist synthesis of implementation and impact
2018     Basque Office for Health Technology Assessment (OSTEBA) [Effectiveness and safety of bone suppression technology for the detection of lung cancer and indications for its use]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tivozanib (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V]
2018     NIHR Health Technology Assessment programme PET-PANC: multicentre prospective diagnostic accuracy and health economic analysis study of the impact of combined modality 18fluorine-2-fluoro-2-deoxy-d-glucose positron emission tomography with computed tomography scanning in the diagnosis and management of pancreatic cancer
2018     Basque Office for Health Technology Assessment (OSTEBA) [Strategies for promoting and strengthening evidence-based nursing in the Basque Country]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Search for guidelines for the update of the DMP "coronary heart disease"]
2018     Belgian Health Care Knowledge Centre (KCE) MammaPrint® test for personalised management of adjuvant chemotherapy decisions in early breast cancer
2018     Basque Office for Health Technology Assessment (OSTEBA) [Checklist for ethical and legal domains analysis]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Support for the development of an S3 guideline on natural childbirth - Evidence reports]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Phlebotonics for venous insufficiency]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cenegermin (moderate or severe neurotrophic keratitis) - Benefit assessment according to §35a (1), Sentence 11, Social Code Book V]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pulsed electromagnetic fields for bone healing disorders]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Endometrial receptivity array in assisted reproduction]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ribociclib (breast cancer) - Addendum to Commission A17-45]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pulsed electromagnetic fields for bone healing disorders - Addendum to Commission E17-08]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [High altitude simulation test for patients with lung disease]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Elvitegravir/cobicistat/emtricitabine/ tenofovir disoproxil (HIV-1 in adolescents) - Benefit assessment according to §35a Social Code Book (SGB) V]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Radiofrequency percutaneous nucleoplasty in disc disorders]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Atezolizumab (non-small cell lung cancer) - Addendum to A17-50]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Thioridazine for the treatment of behavior disorders in patients with intellectual disability]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Perampanel (epilepsy) - Benefit assessment according to §35a Social Code Book (SGB) V]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Pomalidomide combined with dexamethasone in multiple myeloma]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Guselkumab (plaque psoriasis) - Benefit assessment according to §35a Social Code Book V]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Fetoscopic laser photocoagulation in twin-twin transfusion syndrome]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cladribine (multiple sclerosis) - Benefit assessment according to §35a Social Code Book (SGB) V]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Daratumumab for relapsed or refractory multiple myeloma]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dupilumab (atopic dermatitis) - Benefit assessment according to §35a Social Code Book (SGB) V]
2018     NIHR Health Services and Delivery Research programme Understanding new models of integrated care in developed countries: a systematic review
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Rotigotine for Parkinson’s disease]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Assessment of the systematic treatment of parodontopathies]
2018     NIHR Health Technology Assessment programme Surveillance following endovascular aortic aneurysm
2018     NIHR Health Services and Delivery Research programme A staff training intervention to improve communication between people living with dementia and health-care professionals in hospital: the VOICE mixed-methods development and evaluation study
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Endovascular thrombectomy in acute ischemic stroke]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cabozantinib (renal cell carcinoma) - Addendum to Commission A17-56]
2018     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Phototherapy and systemic treatment for moderate to severe psoriasis]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Atezolizumab in non-small cell lung cancer]
2018     Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale (CIUSSS) [Best practices to reduce medication administration errors (MAEs) in hospital centre (HC) and long term care facilities centre (LTCF)]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Niraparib (ovarian cancer) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2018     NIHR Health Technology Assessment programme Adjunctive rifampicin to reduce early mortality from Staphylococcus aureus bacteraemia: the ARREST RCT
2018     NIHR Health Technology Assessment programme (REBALANCE) REview of Behaviour And Lifestyle interventions for severe obesity: AN evidenCE synthesis
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Ramucirumab for advanced gastric or gastroesophageal junction cancer]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Abiraterone acetate (prostate cancer) - Benefit assessment according to §35a Social Code Book V]
2018     NIHR Health Services and Delivery Research programme From programme theory to logic models for multi-specialty community providers: a realist evidence synthesis
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Anti-d immunoglobulin in pregnancy and immune thrombocytopenia]
2018     Canadian Agency for Drugs and Technologies in Health (CADTH) Optimal strategies for the diagnosis of acute pulmonary embolism: a health technology assessment
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cabozantinib (renal cell carcinoma) - Second Addendum to Commission A17-56]
2018     NIHR Health Services and Delivery Research programme Supporting shared decision making for older people with multiple health and social care needs: a realist synthesis to inform emerging models of health and social care
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Lacosamide in epilepsy]
2018     Canadian Agency for Drugs and Technologies in Health (CADTH) Composite resin versus amalgam for dental restorations: a health technology assessment
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Non-invasive determination of the fetal rhesus factor to prevent maternal rhesus sensitization]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Botulinum toxin in adult patients with dystonia]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tivozanib (renal cell carcinoma) - Addendum to Commission A17-58]
2018     Health Information and Quality Authority (HIQA) Guidelines for evaluating the clinical effectiveness of health technologies in Ireland
2018     NIHR Health Technology Assessment programme Treatments for dry age-related macular degeneration and Stargardt disease: a systematic review
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Uvulopalatopharyngoplasty for snoring and obstructive sleep apnea]
2018     Canadian Agency for Drugs and Technologies in Health (CADTH) Drugs for the management of rheumatoid arthritis: clinical evaluation
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Guideline synopsis for the DMP "osteoporosis" - rapid report]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Extended adjuvant endocrine therapy in breast cancer]
2018     Canadian Agency for Drugs and Technologies in Health (CADTH) Metastatic melanoma gap analysis
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dapagliflozin (type 2 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V (new scientific findings)]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Dynamic magnetic resonance imaging for focal liver lesion assessment]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dapagliflozin/metformin (type 2 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V (new scientific findings)]
2018     NIHR Health Technology Assessment programme MRI versus laparoscopy to diagnose the main causes of chronic pelvic pain in women: a test-accuracy study and economic evaluation
2018     NIHR Health Technology Assessment programme Adding emollient bath additives to standard eczema management for children with eczema: the BATHE RCT
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Nabiximols for spasticity and chronic pain]
2018     Canadian Agency for Drugs and Technologies in Health (CADTH) Screening for chlamydia trachomatis and neisseria gonorrhoeae during pregnancy: a health technology assessment
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Alectinib (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Extracorporeal shock wave therapy in musculoskeletal disorders]
2018     Canadian Agency for Drugs and Technologies in Health (CADTH) Clinical evaluation of interventions for the management of insomnia: a review of reviews
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Assessment of the application of fluoride varnish on milk teeth to prevent the development and progression of initial caries or new carious lesions - rapid report]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Genetic testing in primary dystonia]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Brentuximab vedotin (cutaneous T-cell lymphoma) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2018     NIHR Health Technology Assessment programme What works to increase attendance for diabetic retinopathy screening? An evidence synthesis and economic analysis
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Prompt therapy in patients with speech disorders]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Allogeneic T cells (high-risk haematological malignancies) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2018     NIHR Health Technology Assessment programme A pedometer-based walking intervention in 45- to 75-year-olds, with and without practice nurse support: the PACE-UP three-arm cluster RCT
2018     Institut national d'excellence en sante et en services sociaux (INESSS) [Optimal use guide: antibiotic prophylaxis during clean orthopedic surgery in children and adults]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Global postural re-education (RPG®) in spine conditions]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (HIV-infected children) - Benefit assessment according to §35a Social Code Book V]
2018     NIHR Health Technology Assessment programme Screening women aged 65 years or over for abdominal aortic aneurysm: a modelling study and health economic evaluation
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Gait laboratory in patients with gait disorders]
2018     Canary Health Service [Safety, effectiveness, and cost-effectiveness of subcutaneous implantable cardioverter-defibrillator in primary and secondary prevention of sudden cardiac death]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Colorectal cancer screening in persons with a relevant family history - Update to commission S11-01]
2018     NIHR Health Technology Assessment programme Two interferon gamma release assays for predicting active tuberculosis: the UK PREDICT TB prognostic test study
2018     NIHR Health Technology Assessment programme Multiparametric MRI to improve detection of prostate cancer compared with transrectal ultrasound-guided prostate biopsy alone: the PROMIS study
2018     NIHR Health Technology Assessment programme Risk scores to guide referral decisions for people with suspected ovarian cancer in secondary care: a systematic review and cost-effectiveness analysis
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Riluzole in amyotrophic lateral sclerosis]
2018     Canary Health Service [Cost-effectiveness of vaccination against herpes zoster]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ultrasound-guided high-intensity focused ultrasound for malignant neoplasms of the pancreas - second Addendum to Commission H16-02C]
2018     Center for Drug Evaluation (CDE) [HTA for molecular adsorbent recirculating system (MARS)]
2018     NIHR Health Technology Assessment programme Computerised interpretation of the fetal heart rate during labour: a randomised controlled trial (INFANT)
2018     NIHR Health Technology Assessment programme Therapeutic hypothermia to reduce intracranial pressure after traumatic brain injury: the Eurotherm3235 RCT
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Alemtuzumab in multiple sclerosis]
2018     Canary Health Service [Nutritional treatment of adults with chronic kidney disease (CKD) and irreversible severe energy-protein malnutrition using ordinary food]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ocrelizumab (multiple sclerosis) - Benefit assessment according to §35a Social Code Book V]
2018     NIHR Health Technology Assessment programme Everolimus, lutetium-177 DOTATATE and sunitinib for advanced, unresectable or metastatic neuroendocrine tumours with disease progression: a systematic review and cost-effectiveness analysis
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Immunoglobulin in chronic inflammatory demyelinating polyneuropathy and other neurological conditions]